2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
CNS
2
Gastrointestinal
1
Conditions
Brain Neoplasms
2
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
910
Carboplatin
787
pembrolizumab
746
Paclitaxel
744
Bevacizumab
716
Cisplatin
708
Gemcitabine
621
Docetaxel
584
Rituximab
558
Radiotherapy
548
Dexamethasone
511
Nivolumab
491
Doxorubicin
445
Fluorouracil
392
Capecitabine
382
Etoposide
358
Pemetrexed
338
Cytarabine
335
Oxaliplatin
335
Lenalidomide
328
Prednisone
327
Erlotinib Hydrochloride
323
fludarabine phosphate
316
Trastuzumab
305
Leucovorin
299
fludarabine
296
Vincristine
288
Bortezomib
284
Filgrastim
284
Cetuximab
277
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
gadoterate meglumine
×
Clear all
NCT06057168
2026-01-29
GDX-44-016
Guerbet
Phase 3
Completed
138 enrolled
7 charts
NCT01806740
2019-08-08
DCE-MRI
Guerbet
Phase 4
Terminated
37 enrolled
12 charts
NCT02034708
2016-12-30
REMIND
Guerbet
Phase 4
Completed
279 enrolled
9 charts